IN2014MN01907A - - Google Patents

Download PDF

Info

Publication number
IN2014MN01907A
IN2014MN01907A IN1907MUN2014A IN2014MN01907A IN 2014MN01907 A IN2014MN01907 A IN 2014MN01907A IN 1907MUN2014 A IN1907MUN2014 A IN 1907MUN2014A IN 2014MN01907 A IN2014MN01907 A IN 2014MN01907A
Authority
IN
India
Prior art keywords
composition
festinavir
nevirapine
lamivudine
retroviruses
Prior art date
Application number
Inventor
Geena Malhotra
Shrinivas Madhukar Purandare
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Priority to IN1907MUN2014 priority Critical patent/IN2014MN01907A/en
Publication of IN2014MN01907A publication Critical patent/IN2014MN01907A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to a pharmaceutical antiretroviral composition comprising lamivudine festinavir and nevirapine to a process for preparing such a composition and to the use of such a composition for the treatment and/or prophylaxis of diseases caused by retroviruses especially acquired immune deficiency syndrome or an HIV infection.
IN1907MUN2014 2012-03-05 2013-03-05 IN2014MN01907A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN1907MUN2014 IN2014MN01907A (en) 2012-03-05 2013-03-05

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN583MU2012 2012-03-05
PCT/GB2013/000092 WO2013132208A1 (en) 2012-03-05 2013-03-05 Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine
IN1907MUN2014 IN2014MN01907A (en) 2012-03-05 2013-03-05

Publications (1)

Publication Number Publication Date
IN2014MN01907A true IN2014MN01907A (en) 2015-07-10

Family

ID=47884388

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1907MUN2014 IN2014MN01907A (en) 2012-03-05 2013-03-05

Country Status (13)

Country Link
US (1) US20150104511A1 (en)
EP (1) EP2822560A1 (en)
JP (1) JP2015509524A (en)
KR (1) KR20140138837A (en)
CN (1) CN104203244A (en)
AU (1) AU2013229274A1 (en)
BR (1) BR112014021927A2 (en)
CA (1) CA2866133A1 (en)
IN (1) IN2014MN01907A (en)
MX (1) MX2014010337A (en)
RU (1) RU2014140177A (en)
WO (1) WO2013132208A1 (en)
ZA (1) ZA201406495B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2898092A1 (en) * 2013-02-07 2014-08-14 Tobira Therapeutics, Inc. Lamivudine salts
EP3153157A1 (en) 2015-10-09 2017-04-12 Teva Pharmaceutical Works Private Limited Company Pharmaceutical composition for prolonged release of nevirapine
AR112412A1 (en) 2017-08-17 2019-10-23 Gilead Sciences Inc CHOLINE SALT FORMS OF AN HIV CAPSID INHIBITOR
TW202024061A (en) 2017-08-17 2020-07-01 美商基利科學股份有限公司 Solid forms of an hiv capsid inhibitor
KR102587510B1 (en) 2018-02-15 2023-10-11 길리애드 사이언시즈, 인코포레이티드 Pyridine derivatives and their use for treating HIV infection
CA3216031A1 (en) 2018-07-16 2020-01-23 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
SG11202107145SA (en) 2019-01-25 2021-08-30 Univ Brown Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
TW202337439A (en) 2021-12-03 2023-10-01 美商基利科學股份有限公司 Therapeutic compounds for hiv virus infection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK279262B6 (en) 1991-05-16 1998-08-05 Glaxo Group Limited Antiviral combination, pharmaceutical composition containing thereof and its use
GB9622681D0 (en) 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions
AU1534699A (en) * 1997-12-05 1999-06-28 Alza Corporation Osmotic dosage form comprising first and second coats
SK285779B6 (en) 1998-01-16 2007-08-02 Medivir Ab Antiviral compounds
GB9809213D0 (en) 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
EP1610797A1 (en) 2003-03-27 2006-01-04 Boehringer Ingelheim International GmbH Antiviral combination of nevirapine and a further antiretroviral compound
AU2006286314A1 (en) * 2005-08-31 2007-03-08 Cipla Limited Pharmaceutical combinations containing lamivudine, stavudine and nevirapine
ES2574836T3 (en) * 2007-06-08 2016-06-22 Boehringer Ingelheim International Gmbh Nevirapine prolonged release formulation

Also Published As

Publication number Publication date
MX2014010337A (en) 2014-11-14
CN104203244A (en) 2014-12-10
WO2013132208A1 (en) 2013-09-12
WO2013132208A8 (en) 2013-11-07
RU2014140177A (en) 2016-04-27
AU2013229274A1 (en) 2014-09-04
BR112014021927A2 (en) 2019-09-24
JP2015509524A (en) 2015-03-30
KR20140138837A (en) 2014-12-04
EP2822560A1 (en) 2015-01-14
ZA201406495B (en) 2016-03-30
US20150104511A1 (en) 2015-04-16
CA2866133A1 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
IN2013MU01749A (en)
IN2014MN01907A (en)
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12015500713B1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
PH12015501156A1 (en) Pharmaceutical compositions
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
MX358099B (en) Human immunodeficiency virus neutralizing antibodies adn methods of use thereof.
TN2015000185A1 (en) 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group
UA113651C2 (en) MACROCYCLIC PURINS FOR TREATMENT OF Viral INFECTIONS
EA201500383A1 (en) DERIVATIVES 1,2,4-TRIAZINE FOR THE TREATMENT OF VIRAL INFECTIONS
PH12016501968A1 (en) Novel macrocyclic compounds
CY1119957T1 (en) TREATMENT OF PATIENTS WITH THE USE OF ANNOUNCED PHARMACEUTICAL PREPARATION
CY1118074T1 (en) ANTELONOSSIAN FACTORS
DOP2017000086A (en) PHARMACEUTICAL COMPOSITIONS OF PROLONGED ACTION
MX2018006773A (en) Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine.
PH12015502746A1 (en) Prodrug derivatives of substituted triazolopyridines
CY1118913T1 (en) NEW ANTELONOSIC FACTORS
BR112017003252A2 (en) hiv antibody therapy as a treatment substitute
PH12015500322B1 (en) Tris(hetero)arylpyrazoles and use thereof
IN2013CH05288A (en)
JO3641B1 (en) Antiretroviral composition
PH12015502703A1 (en) Pharmaceutical compositions
CY1116711T1 (en) NEW ANTELONOSIC FACTORS